Microglial TNF-α mediates enhancement of dopaminergic degeneration by brain angiotensin

GLIA

Volumn 62, Issue 1, 2014, Pages 145-157

  Borrajo, Ana ^a   Rodriguez Perez, Ana I ^a   Diaz Ruiz, Carmen ^a   Guerra, Maria J ^a   Labandeira Garcia, Jose L ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Dopamine; Glia; NADPH oxidase; Neuroinflammation; Oxidative stress; Parkinson

Indexed keywords

ANGIOTENSIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEUROTOXIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RHO KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL TISSUE; ARTICLE; BRAIN; CELL DEATH; CONTROLLED STUDY; DEGENERATION; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; IN VIVO STUDY; MESENCEPHALON; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRIA; SUBSTANTIA NIGRA;

DOPAMINE; GLIA; NADPH-OXIDASE; NEUROINFLAMMATION; OXIDATIVE STRESS; PARKINSON;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; CELLS, CULTURED; CYCLIC CMP; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; KALLIKREINS; MALE; MESENCEPHALON; MICE; MICE, INBRED C57BL; MICROGLIA; NERVE DEGENERATION; NEURONS; NEUROTOXINS; PANCREATIC EXTRACTS; TETRAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84888091761     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22595     Document Type: Article

References (66)

1. Barcia C, Ros CM, Annese V, Carrillo-de Sauvage MA, Ros-Bernal F, Gómez A, Yuste JE, Campuzano CM, de Pablos V, Fernandez-Villalba E, Herrero MT. 2012. ROCK/Cdc42-mediated microglial motility and gliapse formation lead to phagocytosis of degenerating dopaminergic neurons in vivo. Sci Rep 2:809.
2. Bernhart E, Kollroser M, Rechberger G, Reicher H, Heinemann A, Schratl P, Hallström S, Wintersperger A, Nusshold C, DeVaney T, Zorn-Pauly K, Malli R, Graier W, Malle E, Sattler W. 2010. Lysophosphatidic acid receptor activation affects the C13NJ microglia cell line proteome leading to alterations in glycolysis, motility, and cytoskeletal architecture. Proteomics 10:141-158.
3. Bialecka M, Klodowska-Duda G, Kurzawski M, Slawek J, Gorzkowska A, Opala G, Bialecki P, Sagan L, Droździk M. 2008. Interleukin-10 (IL10) and tumor necrosis factor alpha (TNF) gene polymorphisms in Parkinson's disease patients. Parkinsonism Relat Disord 14:636-640.
4. Budzyn K, Marley PD, Sobey CG. 2006. Targeting Rho and Rho-kinase in the treatment of cardiovascular disease. Trends Pharmacol Sci 27:97-104.
5. Crawford GD Jr, Le WD, Smith RG, Xie WJ, Stefani E, Appel SH. 1992. A novel N18TG2 x mesencephalon cell hybrid expresses properties that suggest a dopaminergic cell line of substantia nigra origin. J Neurosci 12:3392-3398.
6. Crowe PD, Walter BN, Mohler KM, Otten-Evans C, Black RA, Ware CF. 1995. A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J Exp Med 181:1205-1210.
7. Cui R, Tieu B, Recinos A, Tilton RG, Brasier AR. 2006. RhoA mediates angiotensin II-induced phospho-Ser536 nuclear factor kappaB/RelA subunit exchange on the interleukin-6 promoter in VSMCs. Circ Res 99:723-730.
8. Ferger B, Leng A, Mura A, Hengerer B, Feldon J. 2004. Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J Neurochem 89:822-833.
9. Fillit H, Ding WH, Buee L, Kalman J, Altstiel L, Lawlor B, Wolf-Klein G. 1991. Elevated circulating tumor necrosis factor levels in Alzheimer' disease. Neurosci Lett 129:318-320.
10. Fréour T, Jarry A, Bach-Ngohou K, Dejoie T, Bou-Hanna C, Denis MG, Mosnier JF, Laboisse CL, Masson D. 2009. TACE inhibition amplifies TNF-alpha-mediated colonic epithelial barrier disruption. Int J Mol Med 23:41-48.
11. Ganong WF. 1994. Origin of the angiotensin II secreted by cells. Proc Soc Exp Biol Med 205:213-219.
12. Gao X, Hu X, Qian L, Yang S, Zhang W, Zhang D, Wu X, Fraser A, Wilson B, Flood PM, Block M, Hong JS. 2008. Formyl-methionyl-leucyl-phenylalanine-induced dopaminergic neurotoxicity via microglial activation: A mediator between peripheral infection and neurodegeneration? Environ Health Perspect 116:593-598.
13. Garrido-Gil P, Valenzuela R, Villar-Cheda B, Lanciego JL, Labandeira-Garcia JL. 2013. Expression of angiotensinogen and receptors for angiotensin and prorenin in the monkey and human substantia nigra: An intracellular renin-angiotensin system in the nigra. Brain Struct Funct 218:373-388.
14. Gildea JJ. 2009. Dopamine and angiotensin as renal counterregulatory systems controlling sodium balance. Curr Opin Nephrol Hypertens 18:28-32.
15. Grammatopoulos TN, Jones SM, Ahmadi FA, Hoover BR, Snell LD, Skoch J, Jhaveri VV, Poczobutt AM, Weyhenmeyer JA, Zawada WM. 2007. Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. Mol Neurodegener 2:1.
16. Greenwood J, Walters CE, Pryce G, Kanuga N, Beraud E, Baker D, Adamson P. 2003. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J 17:905-907.
17. Han Y, Runge MS, Brasier AR. 1999. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circ Res 84:695-703.
18. Harms AS, Barnum CJ, Ruhn KA, Varghese S, Treviño I, Blesch A, Tansey MG. 2011. Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease. Mol Ther 19:46-52.
19. Harms AS, Lee JK, Nguyen TA, Chang J, Ruhn KM, Treviño I, Tansey MG. 2012. Regulation of microglia effector functions by tumor necrosis factor signaling. Glia 60:189-202.
20. Hiroki J, Shimokawa H, Higashi M, Morikawa K, Kandabashi T, Kawamura N, Kubota T, Ichiki T, Amano M, Kaibuchi K, Takeshita A. 2004. Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. J Mol Cell Cardiol 7:537-546.
21. Hofman FM, Hinton DR, Johnson K, Merrill JE. 1989. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 170:607-612.
22. Honing H, van den Berg TK, van der Pol SM, Dijkstra CD, van der Kammen RA, Collard JG, de Vries HE. 2004. RhoA activation promotes transendothelial migration of monocytes via ROCK. J Leukoc Biol 5:523-528.
23. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S. 1995. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Neurodegeneration 4:257-269.
24. Joglar B, Rodriguez-Pallares J, Rodriguez-Perez AI, Rey P, Guerra MJ, Labandeira-Garcia JL. 2009. The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: Relevance to progression of the disease. J Neurochem 109:656-669.
25. Jones ES, Vinh A, McCarthy CA, Gaspari TA, Widdop RE. 2008. AT2 receptors: Functional relevance in cardiovascular disease. Pharmacol Ther 120:292-316.
26. Khan F, Spicarová Z, Zelenin S, Holtbäck U, Scott L, Aperia A. 2008. Negative reciprocity between angiotensin II type 1 and dopamine D1 receptors in rat renal proximal tubule cells. Am J Physiol Renal Physiol 295:F1110-F1116.
27. Kobori H, Ozawa Y, Acres OW, Miyata K, Satou R. 2011. Rho-kinase/nuclear factor-κβ/angiotensinogen axis in angiotensin II-induced renal injury. Hypertens Res 34:976-979.
28. Kruse MN, Becker C, Lottaz D, Köhler D, Yiallouros I, Krell HW, Sterchi EE, Stöcker W. 2004. Human meprin alpha and beta homo-oligomers: Cleavage of basement membrane proteins and sensitivity to metalloprotease inhibitors. Biochem J 378:383-389.
29. Labandeira-Garcia JL, Rodriguez-Pallares J, Dominguez-Meijide A, Valenzuela R, Villar-Cheda B, Rodríguez-Perez AI. 2013. Dopamine-angiotensin interactions in the basal ganglia and their relevance for Parkinson's disease. Mov Disord 28:1337-1342.
30. Leal MC, Casabona JC, Puntel M, Pitossi FJ. 2013. Interleukin-1β and tumor necrosis factor-α: Reliable targets for protective therapies in Parkinson's Disease? Front Cell Neurosci 7:53.
31. McCoy MK, Ruhn KA, Blesch A, Tansey MG. 2011. TNF: A key neuroinflammatory mediator of neurotoxicity and neurodegeneration in models of Parkinson's disease. Adv Exp Med Biol 691:539-540.
32. McGuire SO, Ling ZD, Lipton JW, Sortwell CE, Collier TJ, Carvey PM. 2001. Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons. Exp Neurol 169:219-230.
33. Mertens B, Vanderheyden P, Michotte Y, Sarre S. 2009. The role of the central renin-angiotensin system in Parkinson's disease. J Renin Angiotensin Aldosterone Syst 11:49-56.
34. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. 1994. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from Parkinsonian patients. Neurosci Lett 165:208-210.
35. Mogi M, Togari A, Tanaka K, Ogawa N, Ichinose H, Nagatsu T. 1999. Increase in level of tumor necrosis factor (TNF)-alpha in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic L-DOPA on the TNF-alpha induction. Neurosci Lett 268:101-104.
36. Ohtsu H, Suzuki H, Nakashima H, Dhobale S, Frank GD, Motley ED, Eguchi S. 2006. Angiotensin II signal transduction through small GTP-binding proteins: Mechanism and significance in vascular smooth muscle cells. Hypertension 48:534-540.
37. Oro C, Qian H, Thomas WG. 2007. Type 1 angiotensin receptor pharmacology: Signaling beyond G proteins. Pharmacol Ther 113:210-226.
38. Padia SH, Kemp BA, Howell NL, Keller SR, Gildea JJ, Carey RM. 2012. Mechanisms of dopamine D(1) and angiotensin type 2 receptor interaction in natriuresis. Hypertension 59:437-445.
39. Pan Q, Yang XH, Cheng YX. 2009. Angiotensin II stimulates MCP-1 production in rat glomerular endothelial cells via NAD(P)H oxidase-dependent nuclear factor-kappa B signaling. Braz J Med Biol Res 42:531-536.
40. Park KM, Bowers WJ. 2010. Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cell Signal 22:977-983.
41. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, Knapp DJ, Crews FT. 2007. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55:453-462.
42. Re RN. 2004. Tissue renin angiotensin systems. Med Clin North Am 88:19-38.
43. Rey P, Lopez-Real A, Sanchez-Iglesias S, Muñoz A, Soto-Otero R, Labandeira-Garcia JL. 2007. Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons. Neurobiol Aging 28:555-567.
44. Righi M, Mori L, De Libero G, Sironi M, Biondi A, Mantovani A, Donini SD, Ricciardi-Castagnoli P. 1989. Monokine production by microglial cell clones. Eur J Immunol 19:1443-1448.
45. Rodriguez-Pallares J, Parga JA, Joglar B, Guerra MJ, Labandeira-Garcia JL. 2012. Mitochondrial ATP-sensitive potassium channels enhance angiotensin-induced oxidative damage and dopaminergic neuron degeneration. Relevance for aging-associated susceptibility to Parkinson's disease. Age (Dordr) 34:863-880.
46. Rodriguez-Pallares J, Rey P, Parga JA, Muñoz A, Guerra MJ, Labandeira-Garcia JL. 2008. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol Dis 31:58-73.
47. Rodriguez-Perez AI, Dominguez-Meijide A, Lanciego JL, Guerra MJ, Labandeira-Garcia JL. 2013. Dopaminergic degeneration is enhanced by chronic brain hypoperfusion and inhibited by angiotensin receptor blockage. Age (Dordr) 35:1675-1690.
48. Rodriguez-Perez AI, Dominguez-Meijide A, Lanciego JL, Guerra MJ, Labandeira-Garcia JL. 2013. Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson's disease. Neurobiol Dis 58:209-219.
49. Rodriguez-Perez AI, Valenzuela R, Villar-Cheda B, Guerra MJ, Lanciego JL, Labandeira-Garcia JL. 2010. Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson's disease. Exp Neurol 224:517-526.
50. Rodriguez-Perez AI, Valenzuela R, Villar-Cheda B, Guerra MJ, Labandeira-Garcia JL. 2012. Different dopaminergic neuroprotection of hormonal replacement therapy in young and aged menopausal rats. Role of the brain angiotensin system. Brain 135:124-138.
51. Scalzo P, Kümmer A, Cardoso F, Teixeira AL. 2009. Increased serum levels of soluble tumor necrosis factor-alpha receptor-1 in patients with Parkinson's disease. J Neuroimmunol 216:122-125.
52. Sen CK, Packer L. 1996. Antioxidant and redox regulation of gene transcription. FASEB J 10:709-720.
53. Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O'Callaghan JP. 2006. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: Role of TNF-alpha. FASEB J 20:670-682.
54. Tarabin V, Schwaninger M. 2004. The role of NF-kappaB in 6-hydroxydopamine- and TNFalpha-induced apoptosis of PC12 cells. Naunyn Schmiedebergs Arch Pharmacol 369:563-569.
55. Tönges L, Frank T, Tatenhorst L, Saal KA, Koch JC, Szego ÉM, Bähr M, Weishaupt JH, Lingor P. 2012. Inhibition of rho-kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease. Brain 135:3355-3370.
56. Varani K, Vincenzi F, Tosi A, Gessi S, Casetta I, Granieri G, Fazio P, Leung E, MacLennan S, Granieri E, Borea PA. 2010. A2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease. FASEB J 24:587-598.
57. Villar-Cheda B, Dominguez-Meijide A, Joglar B, Rodriguez-Perez AI, Guerra MJ, Labandeira-Garcia JL. 2012. Involvement of microglial RhoA/Rho-kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors. Neurobiol Dis 47:268-279.
58. Villar-Cheda B, Rodríguez-Pallares J, Muñoz A, Valenzuela R, Guerra MJ, Baltatu OC, Labandeira-Garcia JL. 2010. Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: Implications for progression of Parkinson's disease. Eur J Neurosci 32:1695-1706.
59. Villar-Cheda B, Valenzuela R, Rodriguez-Perez AI, Guerra MJ, Labandeira-Garcia JL. 2012. Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration. Neurobiol Aging 33:204.e1-11.
60. Wright JW, Harding JW. 2012. Importance of the brain angiotensin system in Parkinson's disease. Parkinsons Dis 2012:860923.
61. Wu D, Teisman P, Tieu K, Vila M, Jackson-Lewis V, Ischiropoulos H, Przedborski S. 2003. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci USA 100:6145-6150.
62. Wu YR, Feng IH, Lyu RK, Chang KH, Lin YY, Chan H, Hu FJ, Lee-Chen GJ, Chen CM. 2007. Tumor necrosis factor-alpha promoter polymorphism is associated with the risk of Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 144B:300-304.
63. Yan J, Zhou X, Guo JJ, Mao L, Wang YJ, Sun J, Sun LX, Zhang LY, Zhou XF, Liao H. 2012. Nogo-66 inhibits adhesion and migration of microglia via GTPase Rho pathway in vitro. J Neurochem 120:721-731.
64. Zawada WM, Banninger GP, Thornton J, Marriott B, Cantu D, Rachubinski AL, Das M, Griffin WS, Jones SM. 2011. Generation of reactive oxygen species in 1-methyl-4-phenylpyridinium (MPP+) treated dopaminergic neurons occurs as an NADPH oxidase-dependent two-wave cascade. J Neuroinflammation 8:129.
65. Zeng C, Liu Y, Wang Z, He D, Huang L, Yu P, Zheng S, Jones JE, Asico LD, Hopfer U, Eisner GM, Felder RA, Jose PA. 2006. Activation of D3 dopamine receptor decreases angiotensin II type 1 receptor expression in rat renal proximal tubule cells. Circ Res 99:494-500.
66. Zhao Z, Huang G, Wang B, Zhong Y. 2013. Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate partially attenuates hippocampal MMP-9 activation and improves cognitive deficits in streptozotocin-induced diabetic rats. Behav Brain Res 238:44-47.